Vanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Vanucizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Vanucizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Vanucizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Vanucizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Vanucizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Vanucizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Vanucizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Vanucizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Vanucizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Vanucizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Vanucizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Vanucizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Vanucizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Vanucizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Vanucizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Vanucizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Vanucizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Vanucizumab. |
| Equol | Equol may increase the thrombogenic activities of Vanucizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Vanucizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Vanucizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Vanucizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Vanucizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Vanucizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Vanucizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Vanucizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Vanucizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Vanucizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Vanucizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Vanucizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Vanucizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vanucizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Vanucizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Vanucizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Vanucizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vanucizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vanucizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Vanucizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vanucizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Vanucizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Vanucizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Vanucizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vanucizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vanucizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Vanucizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vanucizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vanucizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Vanucizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vanucizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Vanucizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Vanucizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Vanucizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vanucizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vanucizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Vanucizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Vanucizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Vanucizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Vanucizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Vanucizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Vanucizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Vanucizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Vanucizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Vanucizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Vanucizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Vanucizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Vanucizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Vanucizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Vanucizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Vanucizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Vanucizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Vanucizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Vanucizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Vanucizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Vanucizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Vanucizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Vanucizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Vanucizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Vanucizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Vanucizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Vanucizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Vanucizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Vanucizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Vanucizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Vanucizumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Vanucizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Vanucizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Vanucizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vanucizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Vanucizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Vanucizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Vanucizumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Vanucizumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Vanucizumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Vanucizumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Vanucizumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Vanucizumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Vanucizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Vanucizumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Vanucizumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Vanucizumab. |